PacBio (NASDAQ: PACB), a leading provider of high-quality, long-read sequencing technologies, today announced that Basecamp Research, a frontier AI lab for therapeutic design, has selected PacBio HiFi ...
PacBio has announced its participation in the 1000 Genomes Long Read Sequencing Project, contributing long-read transcriptome data to enhance this significant human genomics initiative. Through ...
PacBio (NASDAQ: PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher Gibson, Ph.D., to PacBio’s Board of Directors. Dr. Gibson ...
MENLO PARK, Calif., Jan. 13, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today celebrated long-read sequencing being named ...
Organization's 6,000-genome effort will power global ALS research through detailed long-read sequencing data made freely available to scientists worldwide The Importance of Long-Read Sequencing for ...
PACB teams with DNAstack to launch a global HiFi genome network, linking 10,000+ sequences to boost rare disease research without moving data.
The National Institute on Aging’s Long Life Family Study (LLFS) selected PacBio technology to generate genomic and epigenomic data from as many as 7,800 participants. The effort will rely on PacBio’s ...
MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today announced that a UW Medicine and Seattle Children’s ...
Pacific Biosciences of California Inc. (NASDAQ:PACB) on Wednesday announced preliminary revenue of $36.9 million versus a consensus of $33.49 million. The company said the first quarter met ...
Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, recently announced that its HiFi whole-genome sequencing technology has been adopted as a first-line approach in a major ...
Pacific Biosciences of California is back in focus after analysts cut their price target to $1.50 from $2, while a separate fair value estimate was trimmed to $2.43 from $2.50. This shift is tied to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results